Human Metabolome Technologies, Inc. (6090) AI Stock Analysis

• Market Cap: ¥4.00B
• Dividend Yield: 2.35%
• Average Volume (3M): 10.25K
• Price to Earnings (P/E): 20.7
• Beta (1Y): 0.29
• Revenue Growth: -0.82%
• EPS Growth: -21.75%
• Country: JP
• Employees: 58
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -17.10
• Shares Outstanding: 5,919,797
• 10 Day Avg. Volume: 8,100
• 30 Day Avg. Volume: 10,250
• PEG Ratio: 2.95
• Price to Book (P/B): 2.36
• Price to Sales (P/S): 3.09
• P/FCF Ratio: 19.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: ¥770.00 ▲(7.69% Upside)

The stock is supported by strong financial performance, particularly in profitability and balance sheet strength. However, technical indicators suggest bearish momentum, and valuation is moderate. The lack of revenue growth is a concern.

Positive Factors

Balance Sheet Strength

A strong balance sheet with low leverage indicates financial stability and the ability to withstand economic fluctuations, supporting long-term growth.

Profitability

High profitability margins suggest effective cost management and pricing power, which can sustain competitive advantage and shareholder returns over time.

Cash Generation

Strong cash generation relative to net income ensures liquidity and the ability to reinvest in growth opportunities or return capital to shareholders.

Negative Factors

Negative Revenue Growth

Declining revenue growth poses a challenge to sustaining market position and could impact future profitability if not addressed through strategic initiatives.

Cash Flow Volatility

Volatility in cash flow generation can affect the company's ability to fund operations and growth, potentially leading to financial strain during downturns.

Revenue Growth Challenge

Stagnant or declining revenue growth can hinder the company's ability to expand its market presence and invest in new technologies or products, affecting long-term competitiveness.

Human Metabolome Technologies, Inc. Business Overview & Revenue Model

Company Description

Human Metabolome Technologies, Inc. (6090) is a biotechnology company specializing in the analysis of human metabolites to advance the understanding of human health and disease. The company operates primarily in the life sciences sector, offering a range of services that include metabolomics research, biomarker discovery, and diagnostic development. Its core products include advanced analytical platforms and proprietary software for metabolomic data analysis, catering to pharmaceutical companies, academic institutions, and healthcare providers.

How the Company Makes Money

Human Metabolome Technologies generates revenue through multiple streams, primarily by providing metabolomics analysis services to researchers and companies in the pharmaceutical and biotechnology sectors. These services include contract research, where clients pay for specific metabolomic studies or biomarker discovery projects. Additionally, the company earns revenue from the sale of its proprietary analytical platforms and software tools. Strategic partnerships with academic institutions and pharmaceutical companies further enhance its revenue potential by facilitating collaborative research projects and expanding its market reach. Furthermore, the company may also benefit from licensing agreements or collaborations that allow other entities to utilize its technology for their research and development purposes.

Human Metabolome Technologies, Inc. Financial Statement Overview

Summary

The company demonstrates strong profitability with healthy margins and low leverage. However, negative revenue growth presents a challenge.

Income Statement

The company has demonstrated strong profitability with a consistent gross profit margin above 60% and a net profit margin around 17.6% in the latest year. However, revenue growth has been negative at -2.74%, indicating a potential challenge in maintaining top-line growth. The EBIT and EBITDA margins are healthy, suggesting efficient operational management.

Balance Sheet

The balance sheet is robust with a low debt-to-equity ratio of 0.058, reflecting low leverage and financial stability. The return on equity is solid at 13.42%, indicating effective use of equity capital. The equity ratio is strong, suggesting a well-capitalized company with a high proportion of equity financing.

Cash Flow

The company has shown strong free cash flow growth, although the operating cash flow to net income ratio is moderate at 0.83. The free cash flow to net income ratio is healthy at 0.60, indicating good cash generation relative to net income. However, the previous year's negative free cash flow growth highlights potential volatility in cash flow generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.45B	1.46B	1.35B	1.30B	1.22B	1.12B
Gross Profit	921.48M	922.00M	869.33M	859.75M	840.00M	806.02M
EBITDA	342.81M	353.00M	350.31M	319.65M	329.02M	108.33M
Net Income	256.15M	256.00M	243.25M	285.76M	267.79M	58.21M
Balance Sheet
Total Assets	2.37B	2.37B	2.60B	2.29B	2.07B	1.62B
Cash, Cash Equivalents and Short-Term Investments	1.56B	1.56B	1.79B	1.66B	1.50B	1.25B
Total Debt	110.00M	110.00M	226.30M	226.52M	233.19M	152.70M
Total Liabilities	467.00M	467.00M	656.69M	518.73M	582.15M	363.04M
Stockholders Equity	1.91B	1.91B	1.95B	1.77B	1.49B	1.26B
Cash Flow
Free Cash Flow	0.00	225.00M	202.70M	168.11M	177.92M	-62.04M
Operating Cash Flow	0.00	373.00M	236.79M	284.96M	324.03M	-34.17M
Investing Cash Flow	0.00	-197.00M	-32.44M	-116.75M	-152.31M	-25.99M
Financing Cash Flow	0.00	-369.00M	-73.15M	-13.75M	80.49M	86.22M

Human Metabolome Technologies, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 715.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6090, the sentiment is Negative. The current price of 715 is above the 20-day moving average (MA) of 662.00, above the 50-day MA of 664.32, and below the 200-day MA of 716.02, indicating a neutral trend. The MACD of 7.34 indicates Negative momentum. The RSI at 54.29 is Neutral, neither overbought nor oversold. The STOCH value of 74.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6090.

Human Metabolome Technologies, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2395	74 Outperform	¥67.61B	14.52	―	2.79%	28.06%	19.48%
4570	72 Outperform	¥15.83B	49.61	―	―	12.91%	37.96%
4556	69 Neutral	¥5.49B	9.44	―	2.53%	3.14%	-2.85%
6090	67 Neutral	¥4.00B	20.74	―	2.35%	-0.82%	-21.75%
2385	58 Neutral	¥6.33B	38.76	―	2.08%	-10.24%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Human Metabolome Technologies, Inc. Corporate Events

Human Metabolome Technologies Reports Financial Decline in Q3 2025

Human Metabolome Technologies, Inc. reported a significant decline in its quarterly financial performance for September 2025, with net sales dropping by 29.8% compared to the previous year. The company also recorded negative operating and ordinary profits, indicating financial challenges that could impact its market position and stakeholder confidence.

The most recent analyst rating on (JP:6090) stock is a Hold with a Yen770.00 price target. To see the full list of analyst forecasts on Human Metabolome Technologies, Inc. stock, see the JP:6090 Stock Forecast page.